Shionogi & Co., Ltd.





Delayed Japan Exchange 00:30:23 2024-04-19 EDT 5-day change 1st Jan Change
7,117 JPY -0.41% Intraday chart for Shionogi & Co., Ltd. -3.00% +4.68%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Shionogi Completes Up to 75 Billion Yen Share Buyback MT
Tranche Update on Shionogi & Co., Ltd.'s Equity Buyback Plan announced on July 31, 2023. CI
Shionogi & Co., Ltd.'s Equity Buyback announced on July 31, 2023, has closed with 10,842,100 shares, representing 3.73% for ¥74,999.22 million. CI
FunPep Company Limited announced that it has received ¥199.9998 million in funding from Shionogi & Co., Ltd. CI
GSK Unit ViiV Healthcare's Injectable HIV Treatment Shows 'Superior Efficacy' in Late-stage Trial MT
Shionogi Buys Back Shares Worth Nearly 12 Billion Yen MT
GSK says ViiV's cabotegravir study supports longer HIV dose interval AN
GSK's ViiV Healthcare Says Four-month Interval Between Doses Possible for HIV Treatment Cabotegravir MT
Shionogi & Co., Ltd. Announces Xocova Obtains Standard Approval in Japan for the Treatment of SARS-CoV-2 Infection CI
US urges court to preserve Obamacare mandate to cover cancer screenings, HIV drugs RE
GSK's new HIV drug formula could support longer dosing intervals (March 4) RE
GSK Says Data Show For First Time New Ultra Long-Acting Cabotegravir Formulation That Doubles Current Dosing Interval RE
US court to weigh Obamacare mandate to cover HIV drug, cancer screenings RE
FunPep Company Limited announced that it expects to receive ¥199.9998 million in funding from Shionogi & Co., Ltd. CI
Jefferies Adjusts Shionogi’s Price Target to 7,600 Yen From 6,200 Yen, Keeps at Hold MT
PureTech notes positive results from Shionogi's EndeavorRx ADHD trial AN
Akili, Inc. Announces Positive Results from Shionogi & Co., Ltd. Phase 3 Clinical Trial of Localized Version of Akili's Endeavorrx for Pediatric ADHD Patients in Japan CI
Sector Update: Health Care Stocks Ease Late Afternoon MT
Akili Shares More Than Double After Submission of ADHD Treatment for Marketing Approval in Japan MT
Akili's Japan Partner Submits SDT-001 for Marketing Approval in Japan DJ
ViiV Says Trial Data Shows Injectable HIV Treatment Cabenuva Has 'Superior Efficacy' Compared With Pills in Some People MT
ViiV's Long-acting Injectable HIV Drug Shown More Effective than Daily Pills in Phase 3 Study MT
Shionogi & Co., Ltd. Announces New Phase 3 Data Showing Early Resolution of Many Common COVID-19 Symptoms in JAMA Network Open CI
Shionogi Buys Back Over 8 Billion Yen Worth of Shares in January MT
Shionogi's Nine-Month Profit, Revenue Slip on Lower Prescription Drug Sales MT
Chart Shionogi & Co., Ltd.
More charts
Shionogi & Co., Ltd. specializes in development, manufacturing and marketing of pharmaceutical products. The group's activity is organized around 3 families of products: - prescription products: drugs for the treatment of cardiovascular and infectious diseases, diabetes, allergic reactions, etc.; - OTC products: analgesic products, vitamins and tonics, etc.; - diagnosis products: primarily for detection and treatment of cardiovascular diseases and immune system.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Mean consensus
Number of Analysts
Last Close Price
7,146 JPY
Average target price
7,721 JPY
Spread / Average Target
  1. Stock Market
  2. Equities
  3. 4507 Stock
  4. News Shionogi & Co., Ltd.
  5. Shionogi Starts Late-Stage Additional-Dose Trial of Vaccine Against Omicron Subvariant